DCNBIO INFORMATION TECHNOLOGY CO.,LTD
DCNBIO is a Korean biotechnology company specializing in Saccharomyces boulardii probiotics and microbiome therapeutics. We develop clinically proven probiotic solutions for digestive health using proprietary fermentation technology.
About DCNBIO and Microbiome Science
DCNBIO approaches healthcare through the microbiome—the community of bacteria, yeast, and other microorganisms living in the digestive system. Research shows that gut microbiota influences digestion, immune function, metabolism, and even brain health through the gut-brain axis.
The company focuses on Saccharomyces boulardii (S. boulardii), a probiotic yeast that survives stomach acid and reaches the intestines intact. Unlike bacterial probiotics, this yeast strain resists antibiotics, making it useful during antibiotic treatment when bacterial probiotics cannot survive.
Research Focus Areas
- Functional gastrointestinal disorders: Diarrhea, inflammatory bowel conditions, and digestive imbalances
- Metabolic health: Non-alcoholic fatty liver disease and cholesterol management
- Neurodegenerative support: Applications through the microbiome-gut-brain connection
Saccharomyces Boulardii: The Clinically Proven Probiotic Yeast
What is Saccharomyces Boulardii?
Saccharomyces boulardii is a tropical yeast first isolated from lychee and mangosteen fruit. Medical research has studied this strain for decades, confirming its benefits for digestive health.
The yeast works by preventing harmful bacteria from adhering to intestinal walls, producing enzymes that break down toxins, stimulating the immune system to produce protective antibodies, reducing inflammation in the gut lining, and restoring microbial balance after antibiotic use.
Clinical Applications
Studies published in medical journals demonstrate S. boulardii’s effectiveness for:
- Antibiotic-associated diarrhea (reduces occurrence by 50-80%)
- Traveler’s diarrhea prevention
- Inflammatory bowel disease symptom management
- C. difficile infection recurrence prevention
- Irritable bowel syndrome relief
Proprietary Mass Production Technology
DCNBIO developed proprietary fermentation and drying methods to produce S. boulardii at commercial scale. This process requires precise control over fermentation conditions, yeast strain purity, drying technique, and stability testing.
Few companies possess the technical expertise to manufacture S. boulardii reliably. The fermentation process differs from standard yeast production used in baking or brewing. Medical-grade probiotics require higher purity standards and validated potency claims.
Production Capabilities
DCNBIO’s production capacity allows us to supply:
- Probiotic supplement manufacturers
- Pharmaceutical companies developing medical foods
- Private label brands seeking quality S. boulardii ingredients
- Research institutions conducting clinical trials
Product Applications
Dietary Supplements
DCNBIO produces S. boulardii in capsules, sachets, and powder formats. Dosages range from 250mg to 500mg per serving, matching clinical research protocols. Products can be formulated as standalone S. boulardii or combined with other probiotics and prebiotics.
Medical Foods
In some markets, S. boulardii qualifies as a medical food for managing specific digestive conditions under physician supervision. DCNBIO supplies ingredients meeting pharmaceutical-grade quality standards for this application.
Personalized Medicine Tools
DCNBIO develops diagnostic tools for analyzing individual gut microbiota composition. This portable analyzer helps healthcare providers assess current microbiome balance and recommend targeted probiotic interventions.
US Market Expansion
DCNBIO seeks distribution partnerships and wholesale buyers in the United States. The American probiotic market grows annually as consumers become more aware of gut health’s importance to overall wellness.
Target Partners
- Dietary supplement distributors: Companies supplying health food stores and pharmacies
- Private label manufacturers: Brands seeking quality S. boulardii ingredients
- E-commerce platforms: Online retailers specializing in digestive health products
- Healthcare practitioners: Functional medicine doctors, naturopaths, and gastroenterologists
- Pet supplement companies: Manufacturers of veterinary probiotics
Product Customization
DCNBIO offers white label services, custom formulations combining S. boulardii with other probiotics and prebiotics, dosage flexibility tailored to specific use cases, and quality certifications meeting US supplement manufacturing standards.
Why Choose DCNBIO?
Specialized Expertise
Few manufacturers focus exclusively on S. boulardii production. DCNBIO’s entire operation centers on this probiotic yeast, resulting in deep technical knowledge of fermentation conditions, quality control processes specific to yeast probiotics, research partnerships exploring new applications, and supply chain reliability for long-term relationships.
Clinical Foundation
Products based on strains studied in published medical research, not newly discovered or proprietary strains without evidence. Healthcare providers recognize S. boulardii as a clinically validated probiotic.
Korean Quality Standards
South Korea maintains strict regulations for probiotic manufacturing. DCNBIO’s domestic compliance translates to high-quality products for international markets.
Scalable Production
Commercial fermentation capacity supports both small specialty brands and large supplement companies. Production can scale to meet growing demand without compromising quality.
